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Abstract
Retinoblastoma is a cancer that develops within the retina of the eye. Although it
may be found in adults, retinoblastoma cases seen globally are mostly in young children.
Therefore, it is also categorized among the childhood cancers, along with leukemia, bone
cancer, and neuroblastoma.1,2 If retinoblastoma is treated at its initial stages, the cancer is
curable. However, if left untreated, this malignant tumor spreads out from the eye and
may only be treated with enucleation. Enucleation is the last resort to treating the cancer
because it requires the complete removal of the eye. In order to avoid enucleation,
various chemotherapy treatments have been developed, which utilize an array of drugs
such as etoposide. Dunkel et al presented a study that showed successful management of
retinoblastoma with chemotherapy.3 Among the drugs prescribed during chemotherapy,
etoposide was one of them. As an inhibitor of topoisomerase, etoposide directly affects
the growth of retinoblastomas at the core, the DNA, and affects the cell cycle of the
retinoblastoma cells. The result is a reduction in tumor growth; the cells do not properly
divide and cannot contribute to the growth of the tumor.
For this thesis, a hypothetical treatment was created to study the efficacy of
etoposide with a higher dosage on tumor reduction. The dosage was increased from 75
mg/m2 to 90 mg/m2 for a single cycle length of 7 to 15 days. Simultaneously, the dosages
prescribed before the start of the clinical trial will remain unchanged for the duration of
each cycle. Utilizing the higher dosage, it is hypothesized that the higher dosage will
cause a reduction in tumor size among the patients. The higher dosage will be delivered
via a slow-releasing oral capsule. It is hypothesized that the slow-releasing capsule will
allow children to take a higher dosage of the drug for a longer cycle and, therefore, result
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in a significant reduction in tumor size. Although the clinical trial may not be carried out
under the circumstances at the time of this thesis, it is predicted that a large majority of
the patients will present a significant reduction in tumor size.
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Introduction
Purpose
The purpose of this honors thesis is to utilize the information provided through a
review of retinoblastoma and its various treatments available to propose a hypothetical
clinical trial that may potentially be carried out. The hypothetical clinical trial will focus
on etoposide, which is one of the main chemotherapeutic drugs used in treating
retinoblastoma. Etoposide, prescribed with other chemotherapeutic drugs such as
carboplatin and thiotepa, has been found to be effective in the management and reduction
of tumor size.4,5,6 Etoposide, as well as other commonly used chemotherapeutic drugs, is
restricted due to toxic effects on the normal cells and tissues of the body. Young children
form the bulk of patients that receive etoposide in a mixture, or cocktail, of other
chemotherapeutic drugs. Therefore, the proposed clinical trial will present a higher
dosage, which will be taken orally in a time-released oral capsule. By using an extended
release oral dosage, it is hypothesized that the higher dosage will present better results in
terms of the management and reduction of the tumor size.

Background
Retinoblastoma is a malignant tumor of the retina. It is a hereditary disease that
accounts for 4% of all childhood cancers and is most commonly found in children of ages
0-4.7,8 Retinoblastoma appears in the retina as a white mass with many calcifications, or
accumulation of calcium deposits. The mass may develop in various directions.
Retinoblastoma is classified as either intraocular, the tumor is present within the eye, or
extraocular, the tumor has spread to areas around the eye. An intraocular retinoblastoma
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may be bilateral, present in both eyes, or unilateral, present in only one eye. An
extraocular retinoblastoma may be an orbital retinoblastoma or metastic retinoblastoma.
Orbital retinoblastomas are tumors that have only spread to the eye socket. Metastic
retinoblastomas are tumors that have spread to distant parts of the body such as the brain.

Figure 1. Anatomy of the Human Eye – cross-sectional view9
The retina converts the images that enter through the eye’s lens to electrical
signals, which are sent to the brain through the optic nerve. The retina is light-sensitive
and contains photoreceptors, cones and rods across its surface.10 As seen in Figure 1, The
retina is positioned posterior to the lens of the eye and receives a large supply of oxygen
due to the large number of blood vessels present, which gives it its red color.4 The retina
is relatively visible when a light is shown through the pupil as it is dilated. A color
change in the retina may be one of the first signs of a disease. In the case of
retinoblastomas, when the retina is observed through the dilated pupil, leucocoria, a white
tumor, is seen, which marks the beginning stages of the disease.
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Figure 2. Retinoblastoma Samples: (a) Retinoblastoma invasion of the choroid but
not the optic nerve. (b) Retinoblastoma invasion of the optic nerve11
The retinoblastoma cells that become extraocular invade other areas of the eye
including the choroid, as seen in Figure 2.6 In a sample, the tumor cells are distinctly
darker than the cells of the healthy tissue. As the retinoblastoma cells continue to invade
areas around the retina, the healthy tissues are rapidly affected. Eventually, if left
untreated, the retinoblastoma cells will reach the optic nerve. In Figure 2b, the
retinoblastoma cells have proliferated significantly and most of the optic nerve has been
affected; there is little healthy tissue present.
Although fatal if left untreated, retinoblastoma has developed into a curable disease since
its first identification in the 1500s. In 1597, Peter Pawius of Amsterdam was the first person to
provide a description of a tumor of what is now retinoblastoma in a three-year-old. In 1809,
James Warthrop, a Scottish surgeon, of Edinburg defined retinoblastoma as a unique
clinicopathologic entity. The term “retinoblastoma” did not appear until the 1920s, when
Hermann Von Helmholtz, a German physicist and physician, proposed the name. Helmholtz
believed that the tumor arose from embryonic retinal cells. The American Opthalmological
Society adopted the term in 1926. The exact date at which retinoblastoma became curable is not
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known, but treatments were present since the 1930s. The pioneer work on possible treatments for
retinoblastoma was done by Dr. Algernon Reese and Dr. Hayes Martin.12,13 Enucleation had been
the primary option to treat retinoblastoma, but Dr. Reese and Dr. Martion were able to treat and
save patients using radiation therapy.
Retinoblastoma was originally thought to be a fungating mass that resulted in the
destruction of the internal construction of the eye. A fungating mass, or wound, forms when the
growing cancer breaks through the epithelial tissue, or skin.14 However, the extensive molecular
research based on the work of Kyritsis et al. concluded retinoblastoma was a cancer that results
from the overproduction of immature retinal cells. There is also large evidence that genetics is a
factor in the presence of retinoblastoma.15 Chromosomal abnormalities as well as spontaneous
mutation have become key players in identifying and explaining retinoblastoma.
Retinoblastoma cells have shown a distinct rosette-like arrangement (Figure 3).
Predominant retinoblastoma cells are described as “a round cell with basophilic nucleus of
variable size and relatively little cytoplasm.”16 The nuclei present pleiomorphic changes as well
as mitotic figures. As seen in Figure 3, more clearly differentiated areas present the distinct
arrangement seen. The rosette-like arrangement has been determined to be a distinct, or
pathognomonic, characteristic of retinoblastoma. A study performed by Ts’o, Fine, and
Zimmerman revealed the rosettes, formed by cuboidal tumor cells, originated from
photoreceptors and the comparable lining of the lumen of the rosette to the outer membrane of the
retina.17

Figure 3. Retinoblastoma cells that present a rosette-like arrangement.18
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Figure 4: Retinoblastoma cells that form long cell processes.4

Tumor Growth and Diagnosis
Retinoblastoma tumor growth may be endophytic or exophytic. Endophytic
growth represents growth into the vitreous, interior of the eye, which contains a
gelatinous mass, and emerges from the inner layers of the retina. On the other hand,
exophytic growth emerges from the outer layers of the retina and represents growth under
the retina toward the choroid. Retinoblastoma tumor growth may also be a mix of both
endophytic and exophytic growth. Diffuse infiltrating tumor growth represents a grayish
plaque present on the retinal surface. Retinoblastoma may also be identified as
intraocular or extraocular. Intraocular retinoblastoma describes tumor growth that is still
contained within the eye. Extraocular retinoblastoma describes tumor growth that has
spread from the interior of the eye, such as into the optic nerve.
Extraocular retinoblastoma is a risk factor for metastatic growth due to the
invasion into the optic nerve, which creates a more accessible path into the central
nervous system.9 Extraocular retinoblastoma is localized to the optic nerve beyond the
margin of resection or to the soft tissues surrounding the eye.19 The location of tumor
development is a vital factor in determining the amount of visual loss that is experienced.
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In one study, using a visual field analysis, various degrees of visual loss were
examined.20 The patients were placed in one of four groups: no residual defect, absolute
scotoma, arcuate scotoma, and pseudo-visual field defect. Scotoma refers to partial loss
of vision; it may also refer to the presence of a blind spot in normal visual field. Arcuate
represents the shape of the loss of visual field in which the loss of vision begins at a blind
spot and curves around to the nasal field of vision. The relationship between the location
of the tumor to visual loss is that if the tumor is present only at the blind spot, where the
retina is attached to the other nerve, vision is not completely gone. However, once the
tumor begins to move out from the blind spot, vision loss becomes more prominent and
may eventually result in complete vision loss.
Aside from the retina, the optic nerve and the central nervous system are affected
by retinoblastoma. Optic nerve involvement is mostly seen in retinoblastomas due to its
direct connection to the retina. The central nervous system is affected when the disease
has reached a metastatic level. The tumor is classified using the Reese-Ellsworth
classification, which contains five groups, Group I to Group V, based on tumor size and
location.21,22 Group I designates tumors as very favorable for maintenance of sight and
are relatively small. Group I includes solitary tumors that are smaller than 4 disc
diameters (DD), which is based on the size of the optic disc, and multiple tumors that are
no larger than 4 DD. The solitary tumors are at or behind the equator. The equator of the
eye is the plane that is equidistant to the anterior and posterior ends of the eye. Group II
designates tumors as favorable for maintenance of sight and include solitary and multiple
tumors with a size that ranges from 4 DD to 10 DD. The solitary tumors are at or behind
the equator. The multiple tumors are all behind the equator. Group III designates tumors
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as possible for maintenance of sight. This group includes solitary tumors that are larger
than 10 DD and any lesions anterior to the equator. Group IV designates tumors as
unfavorable for maintenance of sight. This group includes multiple tumors that may be
larger than 10 DD and any lesions extending anteriorly to the ora serrata. The ora serrata
is the jagged junction between the retina and ciliary body.23 Group V designates tumors
as very unfavorable for maintenance of sight. This group includes significantly large
tumors that reach a size of one-half of the retina and vitreous seeding. Seeding in
retinoblastoma tumors is seen when small pieces of the tumor have broken off and are
floating around the vitreous.
The Internal Classification of Retinoblastoma (ICRB) is also used to categorize
the various tumors. Unlike the Reese-Ellsworth classification, ICRB categorizes tumors
according to the extent of tumor seeding within the subretinal space and vitreous cavity.
ICRB contains also five categories, A to E, and utilizes tumor size, location and absence
of subretinal and vitreous seeds. As a patient moves up the classification, such as B to E,
it will become more difficult to control the growth of the tumor and preserve as much
useful vision as possible. Patients present in Group A display small intraretinal tumors
that are 3 mm or smaller in greatest dimension and are present away from the foveola and
disc, farther than 3 mm from foveola and 1.5 mm from optic disc. Group B presents all
tumors that are discrete and are confined to the retina; these tumors are distinct from
those present in Group A. Group C presents discrete tumor(s) with minimal subretinal or
vitreous seeding. Subretinal and vitreous seeding refer to tumors that have broken apart
and are present in the subretinal or vitreous portion of the eye. Patients classified into
Group D present tumor(s) that may be massive or diffuse and the disease presents
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significant vitreous or subtretinal seeding. Group E indicates one or more signs of poor
prognosis such as tumor touching the lens of the eye, opaque media from hemorrhage,
and diffuse infiltrating retinoblastoma.3 Patients classified into Group E have limited
treatments available due to the low probability of preserving any vision in the eye.

Figure 5. Slit-lamp photograph of multiple white nodular tumors present in the
inferior anterior chamber.24

Figure 6. Right: Unilateral Retinoblastoma – tumor seeding in the iris. Left:
Vitreous seeding4
In diagnosing retinoblastoma, the most common sign of the presence of
retinoblastoma is leucocoria.3 Leucocoria is the white tumor that is reflected in the
presence of light and blocks the view of the retina. The white tumor is life-threatening
and is the first sign of the tumor growth, which is still contained in the interior of the eye.
The presence of leucocoria in children may be observed if the pupils naturally dilate in
dim light as a beam of light is shone on the eyes. Figures 5 and 6 display the presence of
leucocoria, which may be confined to one area, Figure 5, or spread out, Figure 6.4,15 If the
treatment is begun within 3 to 6 months of discovering leucocoria, retinoblastoma is
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curable; the tumor is still intraocular. The effectiveness of treatment for retinoblastoma
begins to decrease as treatment is delayed after the first sign of leucocoria is discovered.
If the cancer is not responsive to chemotherapy, enucleation is the only option available
to treat retinoblastoma.

Genetics
Genetics plays a large role in the diagnosis and treatment of retinoblastoma.
Retinoblastoma is a hereditary disease when it is transmitted as an autosomal dominant
trait. The autosomal dominant inheritance is present in retinoblastoma that contains a
mutation within the germline, the reproductive cells in the body.25 However, there have
been cases in which retinoblastoma is the result of a de novo mutation. The
retinoblastoma-1 gene has been localized to chromosome 13q14, or more specifically
13q14.2.26,27 According to Online Mendelian Inheritance in Man (OMIM),
retinoblastoma is not the only phenotype that is expressed as a result of microdeletions of
DNA in this region. Microdeletions are chromosomal deletions that span across several
genes but are too small to be detected under the microscope using conventional
cytogenetic methods.28 Cytogenetic analysis is the basic element of diagnosing genetic
disorders caused by chromosomal abnormalities.29 The basic method of cytogenetic
analysis is fluorescence in situ hybridization (FISH). To detect microdeletions, genetic
tests such as microarrays and whole exome sequencing are commonly used. Microarrays
and whole exome sequencing allow a more in depth analysis of the various
microdeletions that may be present on each chromosome. By running a patient’s
chromsomes through a robotic machine, which is able to run hundreds to thousands of
gene sequences placed on a single microscope slide, results obtained immediately present
13

any microdeletions or abnormalities that may have been documented to cause various
diseases.
Aside from retinoblastoma, microdeletions on this chromosome result in somatic
osteosarcoma, somatic bladder cancer, and somatic small cell cancer of the lung.10 The
retinoblastoma gene (RB1) was also the first tumor suppressor to be cloned. The function
of the RB1 gene contains the characteristics of a regulatory element of the cell cycle. The
function of the gene is controlled by a phosphorylation/dephosphorylation mechanism in
various stages of cell proliferation and differentiation.30
The retinoblastoma protein, Rb, functions as an active transcriptional repressor
while it is attached to a promoter through binding with E2F.31 E2F is also known as
Transcription Factor E2F, Retinoblastoma-Binding Protein 3 (RBP3), and
Retinoblastoma-Associated Protein 1 (RBAP1). Rb may interact with transactivating
domains that surround transcription factors on the protein. By surrounding these factors,
the interaction is blocked with a basal transcription complex. Rb can also recruit histone
deacetylase while it is bound to E2F. Histone deacetylation is the removal of negatively
charged acetyl groups to histones.32 Histone acetylation stabilizes the nucleosomes and
prevents transcription. The nucleosomes are induced by histone acetylation to assemble.
Rb is bound to E2F during the recruitment of histone deacetylase and blocks the access of
transcription factors to the promoters. With the formation of Rb-E2F complexes, E2F
sites operate as transcriptional silencers.
When a defective gene copy of chromosome 13q14 undergoes somatic mutation,
the result is the loss of the normal remaining copy of the gene. Experiments have shown
that retinoblastoma tumor formation results in the loss of chromosome during mitotic

14

divisions of predisposed cells.33 According to research done by Zhang et al.,
retinoblastoma showed the lowest mutation rate reported in human cancer to date.34 The
ploidy, a number or set of chromosomes within a cell, of retinoblastoma cells were stable
in vitro and in vivo despite many instances in which retinoblastoma cells presented
mitotic defects. These defects could lead to errors in chromosome segregation.
Heritable retinoblastoma requires two mutations, which includes a mutation in the
germline and another in the developing retina. Germline mutation is present in 90%-95%
of patients with bilateral retinoblastoma.35 In heritable retinoblastoma, an Rb gene
mutation is present in most of the cells of the body, if not all. The Rb gene mutation
results in the inactivation of the both alleles of the Rb gene, which categorizes
retinoblastoma as an autosomal recessive cancer.4 Autosomal recessive retinoblastoma is
found in patients that do not contain a mutation in the germline.20 Non-heritable
retinoblastoma also requires two mutations but both mutations occur in the developing
retina. Due to the presence of the mutation in non-germline cells, patients with autosomal
recessive retinoblastoma usually do not pass on the Rb gene mutations. However, genetic
testing is highly advised to verify the location of the Rb gene mutation.
Those with a de novo mutation cannot be traced back to a family member for
he/she contains a spontaneous mutation that occurred during fertilization. For patients
with retinoblastoma family history, a pedigree may be created from genetic testing to
identify the possibility of having a child with retinoblastoma. Genetic counseling plays an
important role in keeping families educated on the disease as well as providing solutions
to obtain treatment as soon as possible.
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Treatments
As the understanding of retinoblastoma developed, various treatments emerged.
The treatments include enucleation, external beam radiation therapy, focal therapy, laser
photocoagulation, thermotherapy, and system chemotherapy. Enucleation was introduced
by Warthrop after his observation in 1809. Warthrop identified this treatment as a lifesaving measure for patients with retinoblastoma. Enucleation, by definition, involved the
complete removal of the eye containing the tumor. This treatment was performed on
patients in whom extraocular extension had yet to occur. However, during the time of
Warthrop, enucleation was avoided due to high mortality rate after the procedure. The
development of anesthesia, as well as the presence of antibiotics, resulted in fewer
traumas after enucleation and, therefore, reduced the mortality rate. Von Graefe, a
pioneer of German opthamology, identified that retinoblastoma often grew into and down
the optic nerve into the brain. Graefe advised that a long stump of the optic nerve be
removed in the enucleation. This remains the standard practice today.36 Today,
enucleation is used when there is no presumption that any useful vision can be preserved.
Enucleation involves the removal of the eye and may also include the removal of the
optic nerve if it has been invaded. For highly lethal retinoblastomas and Group E tumors,
enucleation is the only solution.
Chemotherapy refers to the use of a drug or chemical to treat an illness. Many
times chemotherapy is automatically thought to refer only to cancer treatment. One type
of chemotherapy is systemic chemotherapy. Systemic chemotherapy uses anticancer
drugs in its treatment, which travels to cells throughout the body through the
bloodstream.37 Another type of chemotherapy is intra-arterial chemotherapy. Intra-aterial
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chemotherapy is a newer treatment that includes intravascular cannulation of the
ophthalmic artery.38 A tube is inserted in the ophthalmic artery to allow direct delivery of
chemotherapy to the eye and areas surrounding the eye.
Stem cell rescue is an approach in treating metatastic retinoblastomas. Stem cell
rescue is a technique that harvests the stem cells of the patient receiving chemotherapy
that uses lethal doses of drugs.39 During the length of the chemotherapy treatment, the
tissue of the bone marrow is heavily destroyed. Therefore, the harvested stem cells are
placed back into the patient after high-dose chemotherapy and used to help the bone
marrow recover from the treatment and make healthy cells. After healthy cells have been
made and replaced in the patient, another cycle of chemotherapy can be performed after
another round of harvesting stem cells, which will be replanted after the treatment. Stem
cell rescue is used to allow patients to undergo many chemotherapy treatments that
require lethal doses of chemotherapeutic drugs.
High-dose chemotherapy, also known as bone marrow transplant, is another
treatment used to treat retinoblastoma. In an experiment by B. Kremens, et. al, high-dose
chemotherapy was performed with thiotepa, an alkylating agent, etoposide, and
carboplatin.40 The dosage for etoposide was 40 mg/kg and the dosage for carboplatin was
1.5 g/m2. The transplantation involves peripheral hematopoietic stem cells and is an
attempt to increase the survival rate of children with metatastic retinoblastomas. For the
children used in the experiment, thiotepa and carboplatin were not prescribed; the drugs
prescribed were BCNU, cyclophosphamide, and etoposide. The dosage used on the child
was 1.6 g/m2. Thiotepa, carboplatin, BCNU, and cyclophosphamide are all alkylating
agents. Alkylating agents work by directly damaging DNA and, therefore, directly
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blocking the cancer cells from reproducing. Alkylating agents target various stages of the
cell phase and used to treat not only retinoblastoma but other cancers as well, such as
leukemia and ovarian cancer.41 Alkylating agents are found to have long-term effects on
the body, such as damage to bone marrow, due to its direct effect on DNA.
Cyclophosphamide belongs to a class of alkylating agents called nitrogen mustards.
Nitrogen mustards are a derivative of nitrogen gas and were discovered to have an effect
on bone marrow and white blood cells. BCNU, or carmustine, belongs to the class of
alkylating agents called nitrosoureas. Nitrosoureas are found to be the most active among
the anticancer drugs “both qualitatively and quantitatively.”42 Nitrosoureas interfere with
the enzymes that are needed for DNA repair and are able to pass the blood-brain barrier,
which represents its involvement in the treatment of retinoblastomas. Thiotepa belongs to
the class of alkylating agents called ethylenimines. Similar to the other classes of
alkylating agents, it interferes with DNA processes and is found to be highly reactive
when protonated. Carboplatin belongs to the class of anticancer drugs called platinum
drugs, which are sometimes grouped with alkylating agents. The mechanism of action of
platinum drugs are similar to that of alkylating agents, but are found to have a lower
chance of causing leukemia later in life. Etoposide belongs in a different group of
anticancer drugs called topoisomerase inhibitors, which interfere with the enzyme
topoisomerase.
Aside from chemotherapy, which utilizes drugs such as etoposide, there are other
treatments available for patients with retinoblastoma. The different types of treatment
include external beam radiation therapy, focal therapy, and ophthalmic artery
chemosurgery. Each treatment tackles various groups of tumor growth and is
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continuously studied and advancing as alternative treatments. Enucleation is a very
common treatment as well, but it is the extreme choice when all other treatments do not
show any signs of improvement. Enucleation is also performed if the patient wishes to
remove the tumor entirely, which may include the optic nerve in certain cases.
External beam radiation therapy has been the preferred vision-sparing treatment
for many years. It is used on progressive or persistent retinoblastomas after chemotherapy
and focal treatment. It is also used on retinoblastoma cases in which vitreous or subretinal
seeding has occurred. Abramson et al. interprets their data to suggest that external beam
radiotherapy may be the only treatment that will potentially cure and spare the patients
from significant long-term visual complications.20
Focal therapy refers to a group of treatments that are applied directly to the eye
and are used on small tumors that are not located at the center of vision or the optic
nerve. For tumors that are determined to be too large for focal therapy, chemotherapy is
the first method of treatment in order to shrink the tumor size. There are three main types
of focal therapy: cryotherapy, laser therapy, and brachytherapy. Cryotherapy is a type of
focal therapy in which an instrument is used to repeatedly freeze the tumor and thaw it at
temperatures as low as -60˚C to -80˚C.43 The tumor cells are targeted and killed through
the process of thawing. The ice crystals penetrate the tumor cell’s membranes.
Cryotherapy is used primarily on small peripheral retinoblastoma tumors. Laser therapy
utilizes heat to physically destroy the tumor cells and is used on small tumors as well as
residual and reoccurring tumors of retinoblastoma. Brachytherapy, also known as
radioactive plaque, consists of a small disc that is surgically placed directly over the
tumor. The disc contains a small amount of radioactive material that is delivered at small
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doses directly to the tumor. The disc is present for two to five days before it is surgically
removed. Brachytherapy is not used on tumors near the optic nerve and/or the center of
vision. However, brachytherapy is used when the retinoblastoma has not responded to
crytotherapy and laser therapy.
Ophthalmic artery chemosurgery is intra-arterial chemotherapy modified.3 It is
delivered through the external carotid artery when the ophthalmic artery cannulation is
impossible. David H. Abramson modifies the chemotherapy treatment by noting that the
largest proportion of the blood flow usually goes to the supratrochlear artery and not
directly to the eye.16 The aim of the experiment is to reduce the dose of melphalan, an
alkylating agent. The results reveal that the lower does had no hematologic toxicity.
Although it was originally used as chemical warfare, its effect on bone marrow and white
blood cells was discovered.44 Also, after treating eyes that were to be enucleated, the
results show that 58% of eyes were saved. Ophthalmic artery chemosurgery makes it
possible to save the most severe of retinoblastomas that would have been enucleated.

Etoposide
Etoposide is a derivative of podophyllotoxin, one of the compounds found in
podophyllin (Figure 7).45 The drug was introduced in 1971 and has become one of the
first-line drugs for treating various cancers. It treats cancers such as small cell lung
cancer, acute nonlymphocytic leukemia, and lymphomas. The effects of etoposide, along
with a large variety of other podophyllotoxin derivations, are mediated by topoisomerase
II and interact with DNA. Topoisomerases are “enzymes that are involved in changing
the supercoiled state of DNA.”46 Topoisomerase II belongs to the second class of
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topoisomerases that cut the ends of both strands of DNA, pass parts of DNA between the
cut ends, and reseal the DNA. Etoposide specifically prompts the breakage of the doublestranded DNA by forming the cleavable complex.47 The cleavable complex is a complex
formed between DNA and topoisomerase II. The cleavable complex creates a toxic effect
due to the conversion of an essential enzyme, topoisomerase II, into a cellular toxin.
Topoisomerase II is an essential enzyme which alters DNA topology and is required to
resolve “knots and tangles” in the genetic material. The knots and tangles are produced
by normal cellular processes, which include DNA replication and recombination.48
Despite the common use of etoposide in cancer treatment, it is found to have moderate
potency, metabolic inactivation, toxic effects, poor water solubility, and may result in the
development of restistance. According to the BC Cancer Manual, the distribution of the
drug depends on a patient’s weight. On average, the prescribed dosage is 32% of a
patient’s body weight, which ranges from 7 to 17 L/m2.49

Figure 7. Etoposide Structure50
Within the five-ring system of podophyllotoxin, the rings labeled A and E in
Figure 8 indicate the pharmacophores. A pharmacophore is portion of the compound that
is responsible for biological activity. Ring A contains a methylenedioxy ring that is
crucial for optimal antitumoral activity. The low potency is due to the hydroxy groups on
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carbon 3 and 5 on ring E. However, despite the low potency, the hydroxyl groups play a
role in the stabilization of topoisomerase II DNA intermediates.18 By modifying the
groups attached to the fourth carbon in ring C, such as bulky groups, the anticancer and
topoisomerase activities are amplified. As can be seen in etoposide, unlike the hydroxyl
group (-OH) attached to carbon 4 in podophyllotoxin, etoposide contains a rather bulky
group at carbon 4 of ring C. Any changes to ring B will lead to a loss of activity.

Figure 8. Structure of Podophyllotoxin43
According to an experiment performed by Debra L. Friedman, et al., etoposide,
prescribed with carboplatin and vincristine, presented positive results for those with
tumors classified as Reese-Ellsworth groups 1-3. By prescribing these drugs during
systemic chemotherapy, treatments became available to treat retinoblastoma and
eliminated enucleation as only option of managing the tumor.51 Etoposide was found to
be effective in treating retinoblastomas and avoiding as the only treatment to control
tumor growth. Etoposide has also been used in the management of metastatic tumor
growth after enucleation.52 Due to the fact that etoposide has shown many positive results
in treating retinoblastoma, a clinical trial can be performed to focus on the effects of
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etoposide. By emphasizing the dosage of etoposide, its effect on treating retinoblastoma
can be more prevalent and, therefore, lead to an array of treatments that may present
positive outcomes.

Hypothesis
Etoposide is commonly taken to treat retinoblastoma. It is specifically chosen for
this hypothetical clinical trial to treat retinoblastoma because, aside from it being a
commonly prescribed drug, it belongs to a class of drugs that directly affect the core of
tumor growth. Tumors are the result of irregular cell growth, which is directly affected by
DNA replication. Etoposide works at the core of DNA replication by damaging the DNA
to prevent any further cells from reproducing. This clinical trial focuses on reducing
tumor growth and, therefore, etoposide is the best drug to prescribe. By targeting the
effects of increasing its dosage, it may provide the treatment needed to reduce tumor
growth. Due to the fact that other drugs are simultaneously taken, the dosage varies
depending on the chemotherapy and the group of tumor growth. In a potential clinical
trial, all patients participating will receive etoposide as well as all other drugs prescribed.
However, the patients that are placed in the experimental group will receive an elevated
dosage of etoposide while the dosages of all other drugs will remain the same. The
patients not in the experimental group will receive the dosage before it was elevated. By
increasing only the dosage of etoposide, it can be assumed that any reduction of tumor
size that occurs will be due to the higher etoposide dosage. The dosage of all other drugs
will not be reduced and remain consistent before, during, and after the trial to focus on
the effect of etoposide. If the experimental group presents reduced tumor size, it can be
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concluded that it is due to the higher etoposide dosage. In other words, if the patients
who do not receive the higher dosage do not show signs of tumor reduction, the
relationship between the higher dosage of etoposide and tumor reduction becomes
clearer. The clinical trial will focus solely on the effect of etoposide as the main drug
with the highest efficacy in the treatment of retinoblastoma tumor growth. As the tumor
growth categorization goes down, such as from B to D, the effect of dosage increase may
not have substantial effects. However, retinoblastomas of group C to E will be included
for this clinical trial to provide random and normal sampling.
The hypothesis for this clinical trial is that when the dosage of etoposide increases
from an average of 75 mg/m2/day to 90 mg/m2/day and taken for single cycle length of 715 days, there will be signs of tumor reduction among the patients. According to the
British Columbia Cancer Agency, BC Cancer Agency, the usual dose of etoposide given
orally is 50 mg – 100 mg PO (orally) once daily for 3-10 days.31 The 3-10 days refer to a
single cycle length, which is a single period of chemotherapy given. In a study performed
Dunkel et al, the etoposide dosage was 250 mg/m2/day for 3 days.3 This dosage is higher
than what is proposed for this hypothetical clinical trial, but given in a shorter period.
Therefore, the dosage that has not been elevated will be 75 mg/m2/day but given for a
longer period. The dosage was also determined based on the draft guidance of etoposide
provided by the U.S. Food and Drug Administration.53 The draft guidance recommends
an oral dosage that is estimated to be twice the dosage given intravenously. It is
hypothesized that the dosage for IV injections is approximately 37 mg/m2/day to 38
mg/m2/day.
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The higher dosage of etoposide has been chosen as the center of this hypothetical
clinical trial because in high-dose chemotherapy, etoposide has shown positive results in
treating the tumor by reducing tumor size.40 By increasing the number of days in a cycle
from 3-20 days to 7-15 days, it is hypothesized that the higher dosage will present a
reduction in tumor size among the patients
What is unique to this hypothetical trial is evaluating the effect of a higher dosage
of etoposide. Like all other chemotherapeutic drugs, to advance in the number of
treatments available, different dosages of etoposide may be tested. However, in other
clinical trials, etoposide is present in a cocktail and the dosages of all drugs vary but are
elevated somewhat equally.54,55,56 By elevating only etoposide within the cocktail and
maintaining the concentrations of the other drugs, the effects of etoposide on tumor
reduction may be observed and analyzed.
Although intravenous (IV) injections are the standard procedure in the distribution
of etoposide and other chemotherapy drugs, for this clinical trial, the focus will be on the
oral distribution, or capsule, of etoposide given each cycle length. There are many FDAapproved dosages for intravenous distribution of etoposide57 On the other hand, there is
only one FDA-approved dosage for the capsule distribution, which is 50 mg distributed
by the drug company Mylan.58 Many clinical trials also focus on various dosages
distributed through IV. Therefore, utilizing the clinical trials that discuss the oral
distribution of etoposide, a hypothetical clinical trial will be created in search of a dosage
that may potentially be FDA-approved and distributed. Despite the focus of oral
distribution for this trial, it is important to know that many patients receive etoposide
intravenously only, orally only, or intravenously and orally. Patients may receive IV
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injections of etoposide during hospitalized stays, but during this trial, the patients will
only receive etoposide orally. All other drugs will continue to be distributed as normal,
which may be IV injections.
A slow-releasing capsule will be used to distribute the higher dosage of etoposide,
which may result in lowering toxicity and alleviate toxic shock. Toxic shock occurs
when the body reacts to healthy cells that are destroyed by drugs used in chemotherapy.
This occurs because drugs prescribed during chemotherapy are poisonous. Therefore, the
drugs are not used for prolonged periods, but in high dosages for short periods of time.
For this trial, the slow-releasing capsule will allow a higher dosage to be prescribed for a
longer single cycle of chemotherapy.
The body weight of the patients selected for this trial will be highly focused due
to its large contribution in the process of determining a safe dosage of etoposide.
Although the dosage is not significantly increased, it is assumed it is high enough to show
results among the younger age group. The higher dosage is assumed to be safe for the
clinical trial, which will be determined through blood work and supervision throughout
the clinical trial.
For this trial, etoposide will be given in a slow-releasing capsule. The effect of a
slow release will potentially reduce the level of toxicity present at the body at one
moment. By controlling the rate at which etoposide will be released into the body, the
level of toxicity may also be controlled. It is hypothesized that a higher dosage of
etoposide could cause the body to react through toxic shock. To mediate, or counteract to
a certain extent, the slow-releasing capsule will provide the parameters to prevent a
severe response to the higher dosage of etoposide. The slow-releasing capsule is also
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used for this clinical trial to study its efficacy of a higher dosage of etoposide for
children. It is hypothesized that the slow-releasing capsule will allow allowing a higher
dosage of etoposide to be prescribed for a prolonged period of time, 7-15 days.The body
will not go into toxic shock as the dosage of etoposide is released in this hypothetical
treatment. There are many drugs currently on the market that utilizes slow-releasing
capsules such as Tylenol and Advil.
James R. Lawter and Michael G. Lanzilotii patented the composition of the
microencapsulation for drugs that are slow-releasing in October 1990. The company that
originally distributed the microencapsulation was the American Cyanamid Company. The
composition of the capsules included the volatile silicone fluids that were used in the
hardening of the capsule. These silicone fluids included octamethylcyclotetrasiloxane and
decamethylcyclopentasiloxane; both molecules are volatile, can be easily evaporated at
room temperature.59 Many slow-releasing capsules are now made with a cellulose
derivative polymer called hydroxypropylmethylcellulose; it is also called methocel.60 As
a cellulose derivative polymer, hydroxypropylmethylcellulose forms a consistent drug
diffusion through the gel that forms when it is hydrated. The release of the drug is
controlled by the diffusion of the drug across the gel and through the dissolution of the
soluble drug into the water, which penetrates into the drug core after it dissolves the
capsule.
In an experiment by A. Solano, et. al, the effects of a sustained release of
etoposide in a poly(ε-caprolactone), PCL, implants were studied.61 Polycaprolactone, a
non-toxic, biodegradable polymer, is used commonly in controlled drug delivery due to
its high permeability to several drugs. It also has the possibility of a long, sustained drug
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release rate and can be fully excreted from the body. Using the Melt Method, etoposide
was thoroughly dispersed into the PCL that had melted. The results of this experiment
showed promising results with approximately 12% of etoposide being released during the
first 15 days in analysis performed on the implant, in vitro. The first phase presented a
small burst of fast release. However, results showed a gradual decrease in release rate
with approximately 66% of etoposide released in the second phase. Results performed in
vivo also presented similar results with approximately 19% of the drug being released
from the implant during the period between the 6th and 25th day of the trial.
Using the results from Solano’s experiment, it can be predicted that the higher
etoposide dosage will be released slowly, which will allow the body to take on the higher
dosage. If the PCL implants were to be utilized for the hypothetical trial, the higher
dosage will have approximately 12%-19% of etoposide released from the implants. There
also would not be safety concerns regarding the long-term effects of using a slowreleasing capsule due to PCL’s ability to be fully excreted from the body. Although the
body may retain levels of etoposide, the effects of the drug will be not be elevated due to
the use of a slow-releasing capsule.

Materials and Methods
In a potential clinical trial, a group of 240 children varying from the ages of 3
months to 10 years will be studied. Hypothetically, 240 children will be chosen to
accommodate for any patients that will have to drop out in the middle of the trial. It is
highly unlikely that the results will be obtained from all 240 children. The reasons behind
why some of the children will be removed from the trial will be discussed in the results
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section. 120 children will be placed in the experimental group and receive the capsule
with the elevated dosage of etoposide. The other 120 children will be placed in the
control group and receive the dosage before it was increased, which is 75 mg/m2/day. The
control group will be used to directly observe the effect of the increased dosage of
etoposide. For both the experimental and control group, all patients will continue to
receive the dosages of all other drugs prescribed prior to the clinical trial. The children
will be recruited from hospitals such as Mount Sinai, New York Presbyterian, and North
Shore. All participants will be chosen randomly among the children that have been
diagnosed with retinoblastoma at any of these hospitals. In order to provide the most
accurate information, ophthalmologists will perform a variety of thorough examinations,
which includes a comprehensive dilated eye exam62 and magnetic resonance imaging
(MRI), on each patient. Neurologists will also study the MRI photos taken to truly
understand the extent of the growth of tumor for each patient. The identification of the
tumor growths of each patient will vary from Group A to Group E, with Group E being
the most severe. Any patients with tumors that have reached the stage at which
enucleation is the only treatment available have been dismissed.
The comprehensive dilated eye exam will be performed to allow an examination
of the interior of the eye seen through the pupil. By widening the pupil, the
ophthalmologists will be able to visualize the extent of the tumor growth to a certain
extent. If the tumor growth has reached Group C in its classification, it should be visible
during this test. The tumor may be immediately visible on the lower region of the iris or
may be visible when the ophthalmologists examine the interior region of the eye,
including the vitreous. The MRI will be done to obtain a more extensive image of the

29

tumor growth within the eye. As seen in Figure 9, the eye that contains the tumor is
substantially larger than the other. However, the size of the eye on the images will not be
the defining characteristic for the presence of a tumor. The MRI images of the patients
will be compared to those of normal subjects, subjects that do not present any
chromosomal abnormalities or presence of tumor growth in the eye. With the results of
the MRI image comparisons, the eligibility of all 300 patients will be verified in order to
continue the clinical trial.

Figure 9. MRI of extraocular extension of retinoblastoma3
Once the patients have been verified, a full physical examination will be
performed. Along with the physical examination, blood work will be completed to record
the blood pressure, iron levels, and cholesterol levels. Blood work will also be performed
specifically to confirm that the patients are not taking any drugs that will affect the
clinical trials by interacting with the pharmacophore of etoposide. Special care will be
taken to ensure the blood work and physical examination is precisely and accurately done
to ensure the right dosage is being given to each patient. This is to ensure no child
receives a dosage that may be lethal to his/her body.
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During the duration of the clinical trial, which will extend from approximately 5
to 10 years, regular blood work as well as renal and hepatic, liver, function will be
performed every 2 weeks for the duration of the trial. These tests will be performed to
closely monitor white blood cells as well as red blood cells to assess the presence of
haematological toxicity.63 Haematological toxicity tests check for neutropenia, anemia,
and thrombocytopenia. Neutropenia is an abnormally low count of white blood cells,
anemia is an inadequate amount of red blood cells to carry oxygen throughout the body,
and thrombocytopenia is a low blood platelet count.64,65,66 Platelets stop bleeding through
clumping, which block the blood vessels. The blood work will be performed regularly to
monitor the levels of etoposide in the body and its relation to haematological toxicity. If
levels of etoposide are detected to be too high, precautions will be taken to ensure the
levels do not become lethal. Precautions will also be taken with any detection of high
levels in regards to haematological toxicity, which may be a sudden fluctuation of white
blood cells, of red blood cells, and/or of blood platelet count. If etoposide levels are
detected to be lethal and signs of haematological toxicity are present, the patients will be
immediately released from the trial. Dilated eye exams and MRIs will also be taken every
6 months for all patients.
The level of toxicity will be evaluated using the Common Toxicity Criteria,
version 2.0, in the case of an adverse event. 67 An adverse event describes any symptom
or disease that is a momentary result of the use of the drug during a treatment or
procedure that may or may not be considered affiliated with the treatment or procedure.
Toxicity levels will be checked at two points during the duration of the trail. The
Common Toxicity Criteria is used to categorize the effects of various drugs administered
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as part of cancer treatments. There are 6 grades: grade 1 represents no adverse event or
within normal limits, grade 1 represents a mild adverse event, grade 2 represents a
moderate adverse event, grade 3 represents a severe and undesirable adverse event, grade
4 represents a life-threatening or disabling adverse event, and grade 5 represents a death
related to adverse event. The first checkpoint will be in 5 years, the halfway point of the
trial. For any patients that are presenting anything greater than grade 2 will receive a
lower dosage. Measures will be taken to ensure all patients stay within grades 0 to 2,
preferably grade 0.

Expected Results
Among the 240 patients that are to participate in this clinical trial, it is assumed
approximately 90% will be able to complete the full trial. It is possible that 24 patients,
will have to drop out of the trial due to different reasons. The reasons may include
moderate to severe side effects to etoposide, such as fainting, hair loss, eye pain,
difficulty breathing or swallowing, and seizures.68 Patients that present any signs of
tumor growth will be removed immediately to ensure the proper treatment and
medications are provided. If the patients have tumors within Group D or E, enucleation
will be performed to prevent any further spread of the tumor.
Side effects are expected regardless of the dosage given. The following side
effects are commonly seen in patients taking etoposide through oral prescriptions: fever,
cough, chills and temporary hair loss.69 Hair is expected to grow back once the etoposide
treatments are completed. In the experiment performed by B. Kremens, et. al, patients
presented side effects such as diarrhea and severe mucositis, which is commonly seen in
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cancer patients undergoing treatments.40 Mucositis occurs when the rapidly dividing
epithelial cells that line the gastro-intestinal tract break down and become vulnerable to
ulcerations and infection. The patients received analgesics, or painkillers, as well as
antibiotics to mediate the effects. Other side effects present were nausea and vomiting.
Similar to the experiment, if any side effects are present in the patients, appropriate
treatments will be given to alleviate them. In an extreme case, if the patients are
experiencing severe side effects that are hindering the effects of etoposide, they will be
removed and treated immediately.
Along with the side effects stated above, the etoposide levels will be thoroughly
checked in internal organs, such as the liver and kidneys. If etoposide levels are found to
be low, the patients will be left to complete the trial. If etoposide levels are found to be
moderate to severely high, the patients will be removed immediately due to the
possibility of liver or kidney damage. The patients will be given the appropriate
treatments to lower etoposide levels and treat any possible signs of liver and kidney
damage.
From the remaining 216 patients that will complete the trial, a success rate will be
determined at approximately 85% of patients with reduced tumors. For the children who
were admitted at the first site of leucocoria, depending on the type of treatment used with
etoposide, the intraocular tumor will be significantly reduced at an increased dosage.

Discussion
The results of this clinical trial may vary depending on the type of patients that
participate. To find accurate results of the effect of increasing the dosage of etoposide, an
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actual clinical trial will have to be performed. Among the 90% who complete the trial, it
is hypothesized that most of the patients who received the elevated dosage presented
reduced tumors. Etoposide is an FDA(U.S. Food and Drug Administration)-approved
drug.70
Etoposide contains properties that target the source of the tumor growth, the
cells. By interrupting the supercoiling of DNA and the cell cycle, the retinoblastoma cells
will not divide as quickly, which will lead to control of tumor growth. A higher dosage
may result in more control, but, without proper guidance and instructions, the higher
etoposide dosage may result in high toxicity levels in the body as well as resistance. It is
assumed that the etoposide was given properly throughout the entire clinical trial, which
includes all proper medications were taken with etoposide, the etoposide was taken at all
proper times, and the etoposide was not mixed with anything that may hinder the effects
of the drug or immensely enhance them.
Resistance is an important factor during this clinical trial. Some of the patients
that do not show reduction in tumor size may be because of resistance to etoposide. One
of the characteristics of etoposide includes possibility of resistance. The resistance may
appear earlier in the clinical trial and may possibly appear after the trial. If the resistance
appears after the trial, it must be taken into account. The follow-ups after the clinical trial
are designed to keep track of the reduction of tumor size without the higher dosage of
etoposide. After observing the patients after the trial, the effects of the higher dosage may
be prevalent because the tumor will respond to the change in medication dosages. The
key results that are obtained will be from the follow-ups as well as the end of the clinical
trial.
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